ETS2 and acute myeloid leukemia: Here, we demonstrate ETS2high as an adverse prognostic biomarker for AML based on analysis of two separate datasets and indicate ETS2high may guide treatment decisions towards allogeneic HCT; we also explore the distinctive gene/microRNA patterns associated with ETS2 expression.